Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-445-0 | CAS number: 106-94-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: inhalation
Administrative data
- Endpoint:
- sub-chronic toxicity: inhalation
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 11 November 2002 - 12 February 2003
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: see 'Remark'
- Remarks:
- Study conducted in compliance with agreed protocols, with no or minor deviations from standard test guidelines and/or minor methodological deficiencies, which do not affect the quality of the relevant results. The study report was conclusive, done to a valid guidelines and the study was conducted under GLP conditions.
Data source
Reference
- Reference Type:
- publication
- Title:
- Unnamed
- Year:
- 2 011
Materials and methods
Test guideline
- Qualifier:
- equivalent or similar to guideline
- Guideline:
- OECD Guideline 413 (Subchronic Inhalation Toxicity: 90-Day Study)
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- 1-bromopropane
- EC Number:
- 203-445-0
- EC Name:
- 1-bromopropane
- Cas Number:
- 106-94-5
- Molecular formula:
- CH3CH2CH2Br
- IUPAC Name:
- 1-bromopropane
Constituent 1
Test animals
- Species:
- rat
- Strain:
- other: F344/N
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Taconic Farms, Inc. (Germantown, NY)
- Age at study initiation: 5 to 6 weeks
- Weight at study initiation: 99 - 102 g (male) and 86 - 92 g (female)
- Fasting period before study: NDA
- Housing: Individually in stainless steel, wire bottom (Lab Products, Inc., Seaford, DE) cages; changed weekly, rotated weekly. Untreated paper cage pan liner (Sheperd Specialty Papers, Kalamazoo, MI); changed daily.
- Diet (e.g. ad libitum): NTP-2000 irradiated pelleted diet (Zeigler Brothers, Inc., Gardners, PA); available ad libitum, except during exposure periods; changed weekly.
- Water (e.g. ad libitum): Tap water (Richland, WA, municipal supply) via automatic watering system (Edstrom Industries, Waterford, WI); available ad libitum.
- Acclimation period: 12 (females) or 13 (males) days
Before the studies began, five male and five female rats were randomly selected for parasite evaluation and gross observation for evidence of disease. Serological analyses were performed on five male and five female sentinel rats during week 1 and five male and five female chamber control rats at the end of the studies.
ENVIRONMENTAL CONDITIONS
- Temperature (°C): Temperature: 72° ± 3° F
- Humidity (%): 50% ± 15%
- Air changes (per hr): 15 ± 2/hour
- Photoperiod (hrs dark / hrs light): 12 hours fluorescent light/day
IN-LIFE DATES: From: 11 November (females) or 12 November (males) 2002 To: 11 February (females) or 12 February (males) 2003
Administration / exposure
- Route of administration:
- inhalation: vapour
- Type of inhalation exposure:
- whole body
- Vehicle:
- air
- Remarks on MMAD:
- MMAD / GSD: Not reported
- Details on inhalation exposure:
- VAPOR GENERATION AND EXPOSURE SYSTEM
A preheater was necessary for the 3-month study. 1-Bromopropane was pumped through a preheater and into a heated glass column filled with glass beads that increased the surface area for vaporization. Heated nitrogen entered the column from below and assisted in vaporizing the chemical while conveying it into a short distribution manifold. Concentration in the manifold was determined by the chemical pump rate and nitrogen flow rate. The pressure in the distribution manifold was kept fixed to ensure constant flow through the manifold and into all chambers as the flow of vapor to each chamber was adjusted.
Metering valves at the manifold controlled flow to each chamber through individual Teflon® delivery lines that carried the vapor from the manifold to three-way exposure valves at the chamber inlets. The exposure valves diverted vapor delivery to exposure chamber exhaust until the generation system was stable and exposures were ready to proceed. To initiate exposure, the chamber exposure valves were rotated to allow the 1-bromopropane vapor to flow to each exposure chamber inlet duct where it was further diluted with filtered, conditioned air to achieve the desired exposure concentration.
The study laboratory designed the inhalation exposure chamber (Harford Systems Division of Lab Products, Inc., Aberdeen, MD) so that uniform vapor concentrations could be maintained throughout the chamber with the catch pans in place. The total active mixing volume of each chamber was 1.7 m3. A small particle detector was used with and without animals in the exposure chambers to ensure that 1-bromopropane vapor, and not aerosol, was produced. No particle counts above the minimum resolvable level (approximately 200 particles/cm3) were detected. - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- VAPOR CONCENTRATION MONITORING
Chamber and room concentrations of 1-bromopropane were monitored by an on-line gas chromatograph. Samples were drawn from each exposure chamber approximately every 20 minutes during each 6-hour exposure period using Hastelloy®-C stream-select and gas-sampling valves in a separate, heated valve oven. The sample lines composing each sample loop were made from Teflon® tubing and were connected to the exposure chamber relative humidity sampling lines at a location close to the gas chromatograph. A vacuum regulator maintained a constant vacuum in the sample loop to compensate for variations in sample line pressure. An in-line flow meter between the vacuum regulator and the gas chromatograph allowed digital measurement of sample flow.
The on-line gas chromatograph was checked throughout the day for instrument drift against an on-line standard vapor of 1-bromopropane in nitrogen supplied by a standard generator. The on-line gas chromatograph was recalibrated as required to meet acceptance criteria. Calibration was performed by comparing chamber concentration data to data from grab samples that were collected with activated coconut charcoal gas sampling tubes, extracted with methylene chloride containing 1-bromobutane as an internal standard, and analyzed using an off-line gas chromatograph. Known volumes of chamber atmosphere were sampled at a constant flow rate ensured by a calibrated critical orifice. The off-line gas chromatograph was calibrated with gravimetrically prepared standards of 1-bromopropane containing 1-bromobutane as an internal standard in methylene chloride.
CHAMBER ATMOSPHERE CHARACTERIZATION
Buildup and decay rates for chamber vapor concentrations were determined with and without animals present in the chambers. At a chamber airflow rate of 15 air changes per hour, the theoretical value for the time to achieve 90% of the target concentration after the beginning of vapor generation (T90) and the time for the chamber concentration to decay to 10% of the target concentration after vapor generation was terminated (T10) was approximately 12.5 minutes. A T90 value of 10 minutes was selected for the 3-month study.
Evaluations of chamber uniformity and persistence and monitoring for 1-bromopropane degradation impurities were conducted periodically throughout the studies by GC. Chamber uniformity was maintained and no degradation was detected. - Duration of treatment / exposure:
- The study was a 3-month repeat dose inhalation study where animals were given full body exposure 5 days a week, for 6 hours per day for 14 weeks.
Animals were exposed for 6 hours and 10 minutes, the 10 minute period at the beginning, being the time for the vapour concentration to reach at least 90% of the target concentration - Frequency of treatment:
- 6 hours per day, 5 days per week, for 14 weeks.
Doses / concentrationsopen allclose all
- Remarks:
- Doses / Concentrations:
62.5 ppm
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
125 ppm
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
250 ppm
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
500 ppm
Basis:
nominal conc.
- Remarks:
- Doses / Concentrations:
1000 ppm
Basis:
nominal conc.
- No. of animals per sex per dose:
- 10 male, 10 female
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: Based on decreased body weights and indications of neurotoxicity at 2,000 ppm in the 2-week study, 1-bromopropane exposure concentrations selected for the 3-month inhalation study in rats were 62.5, 125, 250, 500, and 1,000 ppm.
- Rationale for animal assignment (if not random): Random
- Rationale for selecting satellite groups: NDA
- Post-exposure recovery period in satellite groups: NDA
- Section schedule rationale (if not random): Random
Groups of 10 male and 10 female rats were exposed to 1-bromopropane vapor at concentrations of 0, 62.5, 125, 250, 500, or 1,000 ppm, 6 hours plus T90 (10 minutes) per day, 5 days per week for 14 weeks. Additional clinical pathology groups of 10 male and 10 female rats were exposed to the same concentrations for 23 days. One additional exposure day was scheduled during the last exposure week to give the rats at least 2 consecutive days of exposure before terminal sacrifice. - Positive control:
- None
Examinations
- Observations and examinations performed and frequency:
- Clinical findings were recorded on day 9 (male rats) or 10 and then weekly. Core study animals were weighed initially, on day 9 (male rats) or 10, weekly thereafter, and at the end of the studies.
Animals were anesthetized with carbon dioxide, and blood was collected from the retroorbital sinus of clinical pathology rats on days 3 and 23 and from core study rats at the end of the study for hematology and clinical chemistry analyses. Blood samples for hematology analyses were placed in tubes containing potassium EDTA. Erythrocyte, leukocyte, and platelet counts; hemoglobin; packed red cell volume; mean cell volume; mean cell hemoglobin; and mean cell hemoglobin concentration were determined using an Abbott Cell-Dyn 3700 hematology analyzer (Abbott Diagnostic Systems, Abbott Park, IL). Manual hematocrit values were determined using a microcentrifuge (Heraeus Haemofuge, Germany) and a Damon/IEC capillary reader (International Equipment Company, Needham Heights, MA) for comparison to Cell-Dyn values for packed cell volume. Blood smears for rats were stained with Romanowsky-type aqueous stain in a Wescor 7100 Aerospray Slide Stainer (Wescor, Inc., Logan, UT). Leukocyte differential counts for rats were based on classifying a minimum of 100 white cells. Reticulocytes were stained with New Methylene Blue and enumerated as a reticulocyte:erythrocyte ratio using the Miller disc method (Brecher and Schneiderman, 1950). Blood samples for clinical chemistry analyses were placed in tubes containing separator gel and allowed to clot. After clot retraction occurred, the samples were centrifuged, and the serum was aliquoted for assay of serum chemistry analytes using a Roche Hitachi 912 (Roche Diagnostic Corporation, Indianapolis, IN).
Hematology parameters analysed: hematocrit; packed red cell volume; hemoglobin; erythrocyte, nucleated erythrocyte, reticulocyte, and platelet counts; mean cell volume; mean cell hemoglobin; mean cell hemoglobin concentration; and leukocyte count and differentials
Clinical chemistry parameters analysed: urea nitrogen, creatinine, total protein, albumin, globulin, alanine aminotransferase, alkaline phosphatase, creatine kinase, sorbitol dehydrogenase, and bile acids - Sacrifice and pathology:
- At the end of the study the rats were sacrificed by carbon dioxide asphyxiation and samples were collected for sperm motility and vaginal cytology evaluations on rats exposed to 0, 250, 500, or 1,000 ppm. For 12 consecutive days prior to scheduled terminal sacrifice, the vaginal vaults of the females were moistened with saline, if necessary, and samples of vaginal fluid and cells were stained. Relative numbers of leukocytes, nucleated epithelial cells, and large squamous epithelial cells were determined and used to ascertain estrous cycle stage (i.e., diestrus, proestrus, estrus, and metestrus). Male animals were evaluated for sperm count and motility. The left testis and left epididymis were isolated and weighed. The tail of the epididymis (cauda epididymis) was then removed from the epididymal body (corpus epididymis) and weighed. Test yolk was applied to slides and a small incision was made at the distal border of the cauda epididymis. The sperm effluxing from the incision were dispersed in the buffer on the slides, and the numbers of motile and nonmotile spermatozoa were counted for five fields per slide by two observers. Following completion of sperm motility estimates, each left cauda epididymis was placed in buffered saline solution. Caudae were finely minced, and the tissue was incubated in the saline solution and then heat fixed at 65° C. Sperm density was then determined microscopically with the aid of a hemacytometer. To quantify spermatogenesis, the testicular spermatid head count was determined by removing the tunica albuginea and homogenizing the left testis in phosphate-buffered saline containing 10% dimethyl sulfoxide. Homogenization-resistant spermatid nuclei were counted with a hemacytometer.
Necropsies were performed on all core study animals. The heart, right kidney, liver, lung, spleen, right testis, and thymus were weighed. Tissues for microscopic examination were fixed and preserved in 10% neutral buffered formalin (eyes were fixed in Davidson’s solution for up to 3 days and then transferred to 10% neutral buffered formalin), processed and trimmed, embedded in paraffin, sectioned to a thickness of 4 to 6 μm, and stained with hematoxylin and eosin.
Complete histopathology was performed on 0 and 1,000 ppm core study rats. In addition to gross lesions and tissue masses, the following tissues were examined to a no-effect level: adrenal gland, bone with marrow, brain, clitoral gland, esophagus, eyes, Harderian gland, heart and aorta, large intestine (cecum, colon, rectum), small intestine (duodenum, jejunum, ileum), kidney, larynx, liver, lung, lymph nodes (mandibular, mesenteric, bronchial, mediastinal), mammary gland, nose, ovary, pancreas, parathyroid gland, pituitary gland, preputial gland, prostate gland, salivary gland, skin, spleen, stomach (forestomach and glandular), testis with epididymis and seminal vesicle, thymus, thyroid gland, trachea, urinary bladder, and uterus.
In addition, the liver, larynx, lung and nose of all rats and the prostate gland of male rats were examined in the remaining groups. - Other examinations:
- None
- Statistics:
- See below
Results and discussion
Results of examinations
- Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- effects observed, treatment-related
- Food consumption and compound intake (if feeding study):
- not examined
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- no effects observed
- Clinical biochemistry findings:
- effects observed, treatment-related
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Gross pathological findings:
- effects observed, treatment-related
- Histopathological findings: non-neoplastic:
- effects observed, treatment-related
- Histopathological findings: neoplastic:
- no effects observed
Effect levels
open allclose all
- Dose descriptor:
- NOAEC
- Effect level:
- 125 ppm
- Based on:
- test mat.
- Sex:
- male
- Basis for effect level:
- other: Decreased sperm motility and hepatovellular cytoplasmic vacuolation at 250 ppm air (nominal concentration)
- Dose descriptor:
- NOAEC
- Effect level:
- 250 ppm
- Based on:
- test mat.
- Sex:
- female
- Basis for effect level:
- other: Hepatocellular cytoplasmic vacuolation at 500 ppm air (nominal concentration)
Target system / organ toxicity
- Critical effects observed:
- not specified
Any other information on results incl. tables
All rats survived to the end of the study. The final mean body weight and mean body weight gain of 1,000 ppm males were significantly less than those of the chamber controls. Mean body weights of exposed females were similar to those of the chamber controls.
There were no changes in hematology endpoints that were considered related 1-bromopropane exposure. There were early, transient decreases in albumin and total protein concentrations and alanine aminotransferase activities in most exposed groups of male and female rats. These transient decreases may have been associated with effects of 1-bromopropane on hepatic protein metabolism. Additionally, sorbitol dehydrogenase (SDH) activity was increased at day 23 and at the end of the study in females exposed to 1,000 ppm and at the end of the study in males exposed to 500 or 1,000 ppm. Increased SDH activity would be consistent with mild hepatotoxicity caused by 1-bromopropane.
The absolute and relative liver weights of males exposed to 250 ppm or greater and females exposed to 125 ppm or greater were significantly increased. The absolute spleen weights of females exposed to 125 ppm or greater and the relative spleen weight of 1,000 ppm females were greater than those of the chamber controls. In addition, the absolute and relative right kidney weights of 1,000 ppm females were greater than those of the chamber controls.
There were significant exposure concentration-related decreases in sperm motility in male rats exposed to 250 ppm or greater (6.7%, 10.1%, and 27.7% in the 250, 500, and 1,000 ppm groups, respectively), and there were significant decreases in the number of sperm per gram cauda and the total sperm per cauda (25.2% and 36.8%, respectively), as well as significant decreases in the absolute weights of the cauda (14%) and left epididymis (19%) of 1,000 ppm male rats. Female rats in each of the exposure groups evaluated differed significantly from the chamber controls in the relative amount of time spent in the various estrous cycle stages, with each exposed group spending significantly more time in extended estrus and significantly less time in extended diestrus.
Treatment-related lesions occurred in the liver. There were significantly increased incidences of hepatocellular cytoplasmic vacuolization in males exposed to 250 ppm or greater and in females exposed to 500 or 1,000 ppm. The incidence of hepatocellular vacuolar degeneration was significantly increased in 1,000 ppm females. Hepatocellular cytoplasmic vacuolization consisted of swollen hepatocytes with centrally located nuclei and one to three variably sized vacuoles displacing the cytoplasm. Hepatocellular vacuolar degeneration consisted of a distinct population of enlarged, pale-staining, degenerative, “balloon-like” cells admixed with low numbers of necrotic hepatocytes. The lesion involved hepatocytes surrounding the central vein, but in the most severe cases, the vacuolated hepatocytes extended into the midzonal region.
The incidence of minimal, suppurative, prostatic inflammation in 1,000 ppm males was increased, but the increase was not statistically significant. The increasing trend of this lesion, however, was significant. Because this lesion is a common background finding in F344/N rats, the biological significance of the increased incidence in the 1,000 ppm males is unclear.
Applicant's summary and conclusion
- Conclusions:
- In the 3-month study, there were no treatment-related deaths and significantly lower body weights occurred only in the 1,000 ppm male rat group.
A mild cytoplasmic vacuolization was present in the liver of all 500 and 1,000 ppm rats, and in half of the 250 ppm male rats. Other indications of mild hepatotoxicity in exposed rats were increased liver weights and increases in serum sorbitol dehydrogenase levels.
There were no exposure-related nasal lesions in rats exposed for 3 months. - Executive summary:
Groups of 10 male and 10 female rats were exposed to 1-bromopropane vapor at concentrations of 0, 62.5, 125, 250, 500, or 1,000 ppm, 6 hours plus T90 (10 minutes) per day, 5 days per week for 14 weeks. Additional clinical pathology groups of 10 male and 10 female rats were exposed to the same concentrations for 23 days. All rats survived to the end of the study. Mean body weights of 1,000 ppm males were significantly less than those of the chamber controls. The increases in sorbitol dehydrogenase activities in 500 ppm males and 1,000 ppm males and females were consistent with the histopathologic evidence of mild hepatotoxicity caused by 1-bromopropane. Liver weights of males exposed to 250 ppm or greater and of females exposed to 125 ppm or greater were significantly increased. Spleen and kidney weights of 1,000 ppm females were significantly increased. Results of sperm count and vaginal cytology evaluations showed exposure concentration-related decreases in sperm motility and counts in male rats, reaching 28% and 37%, respectively, in the 1,000 ppm group. Female rats in all three exposure groups evaluated exhibited altered estrous cycles, spending significantly more time in extended estrus and less time in extended diestrus. The incidences of cytoplasmic vacuolization of the liver were significantly increased in males exposed to 250 ppm or greater and in females exposed to 500 ppm or greater. Hepatocyte degeneration was also observed in 1,000 ppm females.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

EU Privacy Disclaimer
På den här webbplatsen används kakor. Syftet är att optimera din upplevelse av den.